Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Inclusion Criteria: * Patients with a diagnosis of multiple myeloma who received bortezomib at a dose of 1.3mg/m2 SQ weekly * No evidence of severe pre-existing peripheral neuropathy, NCI-CTCAE v4.03 =\< 2 * Performance status =\< 2 on the Eastern Cooperative Oncology Group (ECOG) performance scale Exclusion Criteria: * Concurrent use of thalidomide, vincristine, platinum compound, or other agent known to cause significant neuropathy (concurrent lenalidomide will be allowed) * Hospitalization with clinical evidence of active infections as manifested by recurrent fevers, positive blood culture results, or requiring intravenous antibiotic therapy * Inadequate liver and renal function with liver transaminases 3x the upper limit of normal * Glomerular filtration rate (GFR) according to Cockcroft-Gault \< 30 mL/min * Uncontrolled congestive heart failure * Uncontrolled mood disorders * Fasting blood glucose \>150mg/dL or blood sugar (non-fasting) \>200mg/dL if no history of diabetes. Uncontrolled diabetes with HgA1C greater 7% with last evaluation. * Seizure disorder * Monosodium glutamate (MSG) allergy or soy allergy * Life expectancy of shorter than 3 months based on clinical laboratory parameters and the investigator's opinion * Uncorrected Vitamin B12 or folate deficiency on last evaluation. * Use of over the counter (OTC) supplements other than one multivitamin tablet a day * Women who are pregnant or breastfeeding